Jing Gao1, Dimitrios Kalafatis2, Lisa Carlson3, Ida H A Pesonen2,3, Chuan-Xing Li2, Åsa Wheelock2, Jesper M Magnusson4, C Magnus Sköld2,3. 1. Respiratory Medicine Unit, Department of Medicine, Karolinska Institute, Solna, Solnavägen 30, 17176, Stockholm, Sweden. jing.gao@ki.se. 2. Respiratory Medicine Unit, Department of Medicine, Karolinska Institute, Solna, Solnavägen 30, 17176, Stockholm, Sweden. 3. Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden. 4. Department of Internal Medicine/Respiratory Medicine and Allergology, Institute of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
Abstract
BACKGROUND: Observational data under real-life conditions in idiopathic pulmonary fibrosis (IPF) is scarce. We explored anti-fibrotic treatment, disease severity and phenotypes in patients with IPF from the Swedish IPF Registry (SIPFR). METHODS: Patients enrolled between September 2014 and April 2020 and followed ≥ 6 months were investigated. Demographics, comorbidities, lung function, composite variables, six-minute walking test (6MWT), quality of life, and anti-fibrotic therapy were evaluated. Agreements between classification of mild physiological impairment (defined as gender-age-physiology (GAP) stage 1) with physiological and composite measures of severity was assessed using kappa values and their impact on mortality with hazard ratios. The factor analysis and the two-step cluster analysis were used to identify phenotypes. Univariate and multivariable survival analyses were performed between variables or groups. RESULTS: Among 662 patients with baseline data (median age 72.7 years, 74.0% males), 480 had a follow up ≥ 6 months with a 5 year survival rate of 48%. Lung function, 6MWT, age, and BMI were predictors of survival. Patients who received anti-fibrotic treatment ≥ 6 months had better survival compared to untreated patients [p = 0.007, HR (95% CI): 1.797 (1.173-2.753)] after adjustment of age, gender, BMI, smoking status, forced vital capacity (FVC) and diffusion capacity of carbon monoxide (DLCO). Patients with mild physiological impairment (GAP stage 1, composite physiological index (CPI) ≤ 45, DLCO ≥ 55%, FVC ≥ 75%, and total lung capacity (TLC) ≥ 65%, respectively) had better survival, after adjustment for age, gender, BMI and smoking status and treatment. Patients in cluster 1 had the worst survival and consisted mainly of male patients with moderate-severe disease and an increased prevalence of heart diseases at baseline; Cluster 2 was characterized by mild disease with more than 50% females and few comorbidities, and had the best survival; Cluster 3 were younger, with moderate-severe disease and had few comorbidities. CONCLUSION: Disease severity, phenotypes, and anti-fibrotic treatment are closely associated with the outcome in IPF, with treated patients surviving longer. Phenotypes may contribute to predicting outcomes of patients with IPF and suggest the patients' need for special management, whereas single or composite variables have some limitations as disease predictors.
BACKGROUND: Observational data under real-life conditions in idiopathic pulmonary fibrosis (IPF) is scarce. We explored anti-fibrotic treatment, disease severity and phenotypes in patients with IPF from the Swedish IPF Registry (SIPFR). METHODS:Patients enrolled between September 2014 and April 2020 and followed ≥ 6 months were investigated. Demographics, comorbidities, lung function, composite variables, six-minute walking test (6MWT), quality of life, and anti-fibrotic therapy were evaluated. Agreements between classification of mild physiological impairment (defined as gender-age-physiology (GAP) stage 1) with physiological and composite measures of severity was assessed using kappa values and their impact on mortality with hazard ratios. The factor analysis and the two-step cluster analysis were used to identify phenotypes. Univariate and multivariable survival analyses were performed between variables or groups. RESULTS: Among 662 patients with baseline data (median age 72.7 years, 74.0% males), 480 had a follow up ≥ 6 months with a 5 year survival rate of 48%. Lung function, 6MWT, age, and BMI were predictors of survival. Patients who received anti-fibrotic treatment ≥ 6 months had better survival compared to untreated patients [p = 0.007, HR (95% CI): 1.797 (1.173-2.753)] after adjustment of age, gender, BMI, smoking status, forced vital capacity (FVC) and diffusion capacity of carbon monoxide (DLCO). Patients with mild physiological impairment (GAP stage 1, composite physiological index (CPI) ≤ 45, DLCO ≥ 55%, FVC ≥ 75%, and total lung capacity (TLC) ≥ 65%, respectively) had better survival, after adjustment for age, gender, BMI and smoking status and treatment. Patients in cluster 1 had the worst survival and consisted mainly of male patients with moderate-severe disease and an increased prevalence of heart diseases at baseline; Cluster 2 was characterized by mild disease with more than 50% females and few comorbidities, and had the best survival; Cluster 3 were younger, with moderate-severe disease and had few comorbidities. CONCLUSION: Disease severity, phenotypes, and anti-fibrotic treatment are closely associated with the outcome in IPF, with treated patients surviving longer. Phenotypes may contribute to predicting outcomes of patients with IPF and suggest the patients' need for special management, whereas single or composite variables have some limitations as disease predictors.
Authors: Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann Journal: Am J Respir Crit Care Med Date: 2011-03-15 Impact factor: 21.405
Authors: Wim A Wuyts; Katerina M Antoniou; Keren Borensztajn; Ulrich Costabel; Vincent Cottin; Bruno Crestani; Jan C Grutters; Toby M Maher; Venerino Poletti; Luca Richeldi; Carlo Vancheri; Athol U Wells Journal: Lancet Respir Med Date: 2014-11-03 Impact factor: 30.700
Authors: Steven D Nathan; Ashwin Basavaraj; Cristina Reichner; Oksana A Shlobin; Shahzad Ahmad; Joseph Kiernan; Nelson Burton; Scott D Barnett Journal: Respir Med Date: 2010-03-02 Impact factor: 3.415
Authors: Emily C O'Brien; Anne S Hellkamp; Megan L Neely; Aparna Swaminathan; Shaun Bender; Laurie D Snyder; Daniel A Culver; Craig S Conoscenti; Jamie L Todd; Scott M Palmer; Thomas B Leonard Journal: Chest Date: 2020-01-15 Impact factor: 9.410
Authors: Panagiota I Latsi; Roland M du Bois; Andrew G Nicholson; Thomas V Colby; Danai Bisirtzoglou; Ageliki Nikolakopoulou; Srihari Veeraraghavan; David M Hansell; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2003-06-05 Impact factor: 21.405
Authors: Wim A Wuyts; Caroline Dahlqvist; Hans Slabbynck; Marc Schlesser; Natacha Gusbin; Christophe Compere; Sofie Maddens; Klaus-Uwe Kirchgaessler; Karen Bartley; Benjamin Bondue Journal: BMJ Open Respir Res Date: 2018-11-21
Authors: Dragana M Jovanovic; Martina Šterclová; Nesrin Mogulkoc; Katarzyna Lewandowska; Veronika Müller; Marta Hájková; Michael Studnicka; Jasna Tekavec-Trkanjec; Simona Littnerová; Martina Vašáková Journal: Respir Res Date: 2022-05-27
Authors: Qiang Zheng; Ingrid A Cox; Julie A Campbell; Qing Xia; Petr Otahal; Barbara de Graaff; Tamera J Corte; Alan K Y Teoh; E Haydn Walters; Andrew J Palmer Journal: ERJ Open Res Date: 2022-03-14
Authors: Dimitrios Kalafatis; Anna Löfdahl; Per Näsman; Göran Dellgren; Åsa M Wheelock; Linda Elowsson Rendin; Magnus Sköld; Gunilla Westergren-Thorsson Journal: Int J Mol Sci Date: 2021-12-14 Impact factor: 5.923